Geom Therapeutics Company
Geom Therapeutics is a biotechnology company.
Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for multidrug-resistant Gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, their lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. They are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. They have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Their mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies.
Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for multidrug-resistant Gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, their lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. They are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. They have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Their mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies.
Technology:
Preventive Medicine
Industry:
Precision Medicine
Headquarters:
San Francisco
Founded Date:
2015
Employees Number:
1-10
Funding Status:
undisclosed
Register and Claim Ownership